5.4.3 Lack of Proper Testing and Approval Processes

Introduction

The testimonies from the NCI hearings in Regina raised critical issues regarding the inadequacies in the testing and approval processes of COVID-19 vaccines. Key testimonies highlighted the expedited approval processes, the lack of thorough preclinical and clinical testing, and the potential conflicts of interest within regulatory bodies. These concerns are supported and further elaborated upon by findings in the November 28, 2023 NCI Report.

Testimonies on Inadequate Testing and Approval Processes

Dr. Robert Chandler

• Key Points: Dr. Chandler emphasized that the Pfizer vaccine trials were flawed due to the unblinding of the control group, which undermined the integrity of the trials. The unblinding meant that participants knew whether they received the vaccine or a placebo, which could bias the reporting of symptoms and outcomes.

• Lack of Comprehensive Testing: He pointed out significant gaps in the testing protocols, including the absence of long-term safety data. The trials primarily measured short-term reactogenicity (e.g., COVID-like symptoms) for only seven days post-injection and followed severe symptoms for up to six months, which is insufficient for a comprehensive safety profile.

Dr. Jessica Rose

• VAERS Data: Dr. Rose presented data showing underreporting of adverse events by a factor of 31 times, which indicated that the actual number of adverse reactions would be much higher than what is reported. The VAERS data showed a substantial increase in adverse events and deaths associated with COVID-19 vaccines compared to influenza vaccines.

General Issues with Fast-Track Approval

• Expedited Approval Process: Many testimonies criticized the fast-track approval process, which bypassed several critical stages of traditional vaccine development. Normally, vaccine development involves a timeline of 5–10 years, including in-vitro, animal testing, and three phases of human trials. These steps ensure the safety and efficacy of the vaccines before they are approved for public use.

• Economic Pressures: There were concerns that economic motivations, such as attracting foreign investment and promoting innovation, were prioritized over safety. The regulatory changes introduced in Canada aimed to reduce barriers to bringing advanced therapeutic treatments to market, which included expedited clinical trials and product authorizations.

Corroborating Evidence from the 2023 NCI Report

• Historical Safety Requirements: The 2023 NCI Report highlighted the importance of maintaining rigorous safety standards for drug approval. It emphasized that the new regulatory processes allowed for the approval of COVID-19 vaccines without the usual requirement to prove safety and efficacy through randomized-controlled-trials (RCTs). This undermined the precautionary principle that has traditionally governed drug approval.

• Lack of Long-Term Studies: The 2023 NCI Report noted the absence of mid-term and long-term safety studies for the COVID-19 vaccines. This is critical because long-term effects, particularly for gene therapies like mRNA vaccines, are unknown and require extensive follow-up.

• Conflict of Interest and Independence: There were concerns about conflicts of interest within Health Canada and its reliance on pharmaceutical companies for funding. The 2023 NCI Report recommended establishing an independent body to conduct safety reviews and ensure that regulatory decisions are made based on citizen health considerations rather than political or economic motivations.

Case Study: Pfizer Vaccine Trials

• Disproportionate Participant Exclusions: The 2023 NCI Report highlighted the disproportionate exclusion of participants from efficacy evaluations due to protocol deviations, which skewed the results. In the Pfizer trials, a significant number of participants in the vaccine arm were excluded compared to the placebo arm, raising questions about the validity of the reported efficacy.

• Real-World Data vs. RCTs: The 2023 NCI Report also pointed out discrepancies between real-world data and the results of the RCTs. For instance, the real-world effectiveness of the vaccines was lower than reported in the trials, partly due to methodological biases and the lack of systematic testing of all participants.

Recommendations

The testimonies and findings from the NCI Report underscore the need for:

1. Immediately Discontinuing Use of mRNA vaccines.

2. Reverting to Rigorous Approval Standards: The new expedited approval processes should be revoked, and Health Canada should return to its historical safety requirements that ensure comprehensive preclinical and clinical testing before approval.

3. Ensuring Transparency: Regulatory changes should be transparent, involving public consultation and clear communication with stakeholders, including healthcare professionals and the public.

4. Independent Oversight: Establishing an independent body to conduct safety reviews free from industry influence is crucial for maintaining public trust and ensuring patient safety.

5. Strengthening Post-Market Surveillance: Continuous monitoring of approved pharmaceuticals is essential to detect and address any safety concerns that may arise over time.

6. Balancing Innovation and Safety: While promoting innovation is important, it should not compromise patient safety. Long-term effects of novel drugs must be considered, and ethical considerations should be integrated into the approval process.